These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 20147978)
21. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907 [TBL] [Abstract][Full Text] [Related]
22. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. de Lima M; Giralt S Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044 [TBL] [Abstract][Full Text] [Related]
23. Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Wong E; Mason K; Collins J; Hockridge B; Boyd J; Gorelik A; Szer J; Ritchie DS Biol Blood Marrow Transplant; 2017 May; 23(5):840-844. PubMed ID: 28167152 [TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. Kerbauy FR; Rodrigues M; de Souza Santos FP; Sobrinho JN; Kutner JM; Torres MA; Ribeiro AA; de Lima M; Hamerschlak N Leuk Lymphoma; 2011 Feb; 52(2):321-4. PubMed ID: 21281240 [No Abstract] [Full Text] [Related]
25. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634 [TBL] [Abstract][Full Text] [Related]
27. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Nelson RP; Yu M; Schwartz JE; Robertson MJ; Hromas R; Fausel CA; Vance GH; Dlouhy SR; Baute JA; Cox EA; Wood LL; Srivastava S; Robertson KA; Haut PR; Farag SS; Abonour R; Cornetta K; Cripe LD Bone Marrow Transplant; 2010 Aug; 45(8):1300-8. PubMed ID: 20062092 [TBL] [Abstract][Full Text] [Related]
28. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898 [TBL] [Abstract][Full Text] [Related]
29. [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies]. Nakamura Y; Mori T; Kato J; Aisa Y; Nakazato T; Shigematsu N; Okamoto S Rinsho Ketsueki; 2012 Mar; 53(3):318-22. PubMed ID: 22499048 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. Lim Z; Brand R; Martino R; van Biezen A; Finke J; Bacigalupo A; Beelen D; Devergie A; Alessandrino E; Willemze R; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; Kroger N; Mufti GJ; De Witte TM J Clin Oncol; 2010 Jan; 28(3):405-11. PubMed ID: 20008642 [TBL] [Abstract][Full Text] [Related]
34. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618 [TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy. Kawashima N; Inamoto Y; Sato T; Nakashima M; Kagaya Y; Watakabe K; Seto A; Fukushima N; Kurahashi S; Ozawa Y; Miyamura K Bone Marrow Transplant; 2016 Jun; 51(6):869-71. PubMed ID: 26878661 [No Abstract] [Full Text] [Related]
37. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML. O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364 [TBL] [Abstract][Full Text] [Related]
38. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Shimoni A; Nagler A Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090 [TBL] [Abstract][Full Text] [Related]